Q1 EPS Forecast for Bristol Myers Squibb Raised by Analyst

Bristol Myers Squibb Company (NYSE:BMY) – Equities researchers at Zacks Research raised their Q1 2026 earnings estimates for shares of Bristol Myers Squibb in a research report issued to clients and investors on Wednesday, September 17th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will earn $1.48 per share for the quarter, up from their previous forecast of $1.45. The consensus estimate for Bristol Myers Squibb’s current full-year earnings is $6.74 per share. Zacks Research also issued estimates for Bristol Myers Squibb’s FY2026 earnings at $5.90 EPS.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating the consensus estimate of $1.07 by $0.39. The firm had revenue of $12.27 billion during the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The business’s quarterly revenue was up .6% compared to the same quarter last year. During the same period in the prior year, the company earned $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS.

A number of other equities analysts have also recently issued reports on BMY. Daiwa America cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Morgan Stanley restated a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup dropped their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research note on Friday, August 1st. Daiwa Capital Markets cut shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research note on Tuesday, August 5th. Finally, Wall Street Zen cut shares of Bristol Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 6th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $56.38.

Bristol Myers Squibb Trading Down 1.3%

Shares of BMY stock opened at $45.56 on Thursday. Bristol Myers Squibb has a 52-week low of $42.96 and a 52-week high of $63.33. The stock has a market cap of $92.74 billion, a price-to-earnings ratio of 18.37, a P/E/G ratio of 2.36 and a beta of 0.35. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The firm has a fifty day moving average of $46.97 and a 200-day moving average of $49.83.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of BMY. Brighton Jones LLC boosted its stake in shares of Bristol Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock valued at $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Bank Pictet & Cie Europe AG bought a new position in shares of Bristol Myers Squibb in the 4th quarter valued at about $13,094,000. Westwood Holdings Group Inc. raised its position in shares of Bristol Myers Squibb by 397.2% in the 4th quarter. Westwood Holdings Group Inc. now owns 25,191 shares of the biopharmaceutical company’s stock valued at $1,425,000 after acquiring an additional 20,124 shares during the period. Waverly Advisors LLC raised its position in shares of Bristol Myers Squibb by 140.0% in the 4th quarter. Waverly Advisors LLC now owns 32,099 shares of the biopharmaceutical company’s stock valued at $1,816,000 after acquiring an additional 18,722 shares during the period. Finally, NCM Capital Management LLC raised its position in shares of Bristol Myers Squibb by 1.1% in the 4th quarter. NCM Capital Management LLC now owns 21,626 shares of the biopharmaceutical company’s stock valued at $1,223,000 after acquiring an additional 238 shares during the period. Institutional investors own 76.41% of the company’s stock.

Insider Activity

In other news, EVP David V. Elkins sold 56,000 shares of the firm’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total value of $2,650,480.00. Following the transaction, the executive vice president owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This trade represents a 25.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.09% of the company’s stock.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Stockholders of record on Friday, October 3rd will be paid a $0.62 dividend. This represents a $2.48 annualized dividend and a dividend yield of 5.4%. The ex-dividend date of this dividend is Friday, October 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.